Payment overview · 2025
General Payments
$357.49
19 reported records · 11 companies
Healthcare provider profile · identity verified
Yashashree L Bethala, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BILOXI, MS · NPI 1659333052
Verified facts
What the public records show
CMS Open Payments records show Yashashree L Bethala, MD received $357.49 in general payments during 2025 across 19 reported records.
PFIZER INC. accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $94.99 | 26.6% | 5 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $69.94 | 19.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.93 | 12.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.83 | 6.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.34 | 6.0% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $21.03 | 5.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.38 | 5.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.98 | 5.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.20 | 4.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.96 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.91 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $357.49 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $69.94 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $48.75 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.52 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.52 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
131 | 30 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 465 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 420 | 101 |
| Losartan Potassium | Losartan Potassium | 345 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 85 |
| Lisinopril | Lisinopril | 220 | 65 |
| Omeprazole | Omeprazole | 161 | 49 |
| Metformin Hcl | Metformin Hcl | 152 | 50 |
| Gabapentin | Gabapentin | 151 | 50 |
| Simvastatin | Simvastatin | 139 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 45 |
| Synthroid | Levothyroxine Sodium | 131 | 30 |
| Potassium Chloride | Potassium Chloride | 117 | 36 |
| Sertraline Hcl | Sertraline Hcl | 117 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 26 |
| Furosemide | Furosemide | 93 | 32 |
| Januvia | Sitagliptin Phosphate | 93 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 26 |
| Carvedilol | Carvedilol | 89 | 23 |
| Famotidine | Famotidine | 87 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 25 |
| Methylprednisolone | Methylprednisolone | 77 | 63 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 64 |
| Bupropion Xl | Bupropion Hcl | 75 | 19 |
| Allopurinol | Allopurinol | 67 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 17 |
| Glimepiride | Glimepiride | 64 | 15 |
| Metformin Hcl Er | Metformin Hcl | 64 | 21 |
| Trazodone Hcl | Trazodone Hcl | 64 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 14 |
| Ozempic | Semaglutide | 59 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 11 |
| Eliquis | Apixaban | 56 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 16 |
| Montelukast Sodium | Montelukast Sodium | 54 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 15 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 48 | 17 |
| Clonidine Hcl | Clonidine Hcl | 47 | 14 |
| Alprazolam | Alprazolam | 46 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 41 | 33 |
| Donepezil Hcl | Donepezil Hcl | 39 | 11 |
| Valacyclovir | Valacyclovir Hcl | 39 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | 16 |
| Atenolol | Atenolol | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Valsartan | Valsartan | 35 | 13 |
| Cefuroxime | Cefuroxime Axetil | 34 | 30 |
| Estradiol | Estradiol | 32 | 18 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 30 | 30 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 14 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | 11 |
| Fluconazole | Fluconazole | 28 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 14 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 13 |
| Prolia | Denosumab | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Azithromycin | Azithromycin | 16 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $357.49 · 19 records | PFIZER INC. | ABRYSVO, CAPLYTA, COMIRNATY, DAYBUE, Fluad, Flucelvax, Kerendia, Korlym, MCOT, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, UBRELVY, VRAYLAR, VYNDAMAX, VYNDAQEL, Wegovy, YUPELRI, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error